References

Once-weekly semaglutide in adults with overweight or obesity

10.1056/nejmoa2032183 · 2021 · External reference

Tirzepatide once weekly for the treatment of obesity

10.1056/nejmoa2206038 · 2022 · External reference

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

10.1016/s2213-8587(22)00340-0 · 2023 · External reference

Unresolved reference

External reference

GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art

10.1016/j.molmet.2020.101102 · 2021 · External reference

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

10.1111/dom.14280 · 2021 · External reference

Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial

10.1002/oby.23481 · 2022 · External reference

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

10.1111/dom.12932 · 2017 · External reference

Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic

10.1002/oby.23120 · 2021 · External reference

Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index

10.1046/j.1365-2036.2003.01612.x · 2003 · External reference

Gastroparesis

10.1038/s41572-018-0038-z · 2018 · External reference